雖然已經有針對疫苗混打的研究了,但在現實中,各國政府對疫苗的選擇及施打仍受限於經費與供給量能。
"Complicating both questions are the different technologies being used in the world’s armory of vaccines. Shots that use an inactivated virus to stimulate the immune system might perform differently from others that use messenger RNA, a molecule that directs cells to make antibodies against the virus. Little is known about the risk of side effects from multiple doses.
Governments considering booster programs also face logistical hurdles, such as whether to vaccinate everyone or just the elderly and vulnerable."
莫德納提出生物製品許可申請(BLA),FDA在審視安全性時也注意到12-17之間的青少年預防作用和成人組有相近效果。另一家輝瑞也是提出BLA申請了。
https://www.axios.com/moderna-coronavirus-vaccine-fda-6711dc5e-bcd5-4d20-8daf-807f13df0850.html
莫德納聲明:
[“We thank Taiwan for their support in securing this new agreement to supply in 2022 and 2023 our mRNA COVID-19 vaccine and our updated variant booster candidate, if approved,” said Stéphane Bancel, Moderna’s Chief Executive Officer. “We remain committed to making our vaccine available around the world.” ]
https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-new-supply-agreement-taiwan-20-million-doses